Literature DB >> 30317773

[Study on the effects of target-silencing CXCR3 expression on malignant proliferation of hepatocellular carcinoma].

Y Ren1, Y Z Kan, L F Kong.   

Abstract

Objective: To explicit, the expression of chemokine receptor 3 in HCC tissues and its relationship with overall survival of patients, and to explore the effect of targeted silencing CXCR3 gene on proliferation of hepatocellular carcinoma cells and its mechanism of action.
Methods: The expression of CXCR3 in 60 cases of hepatocellular carcinoma and its adjacent tissues were detected by immunohistochemistry. The clinicopathological correlations between the expression levels of CXCR3 in hepatoma tissues of liver cancer patients were analyzed and univariate Kaplan-Meier survival analysis was performed in combination with follow-up data. Huh7 hepatoma cells were infected with lentivirus LV-CXCR3-shRNA. The effects of CXCR3 deletion on proliferation of hepatoma cells were determined by CCK-8 assay and tumor-bearing nude mice experiment.
Results: CXCR3 was highly expressed in HCC tissues, and the overall survival rate (OS) of patients with high CXCR3 expression was significantly lower than that of patients with low expression. After the CXCR3 gene was successfully silenced in Huh7 hepatocellular carcinoma cells, the proliferation ability of Huh7 cells was significantly inhibited in vitro, and the tumor growth rate of nude mice was slowed down, and the activity of JAK-STAT pathway in Huh7 cells was decreased, and the levels of c-MYC and Bcl-xl protein were decreased. In addition, deletion of CXCR3 can effectively inhibit IL-6-mediated JAK-STAT pathway activation.
Conclusion: CXCR3 high expression indicated that the survival rate was poor, and the target silencing of CXCR3 gene could inhibit the proliferation of hepatocellular carcinoma cells and maybe related to inhibition of JAK-STAT pathway activity. CXCR3 may be a potential target for the treatment of hepatocellular carcinoma.

Entities:  

Keywords:  Carcinoma, hepatocellular; JAK-STAT pathway; Neoplasms; Receptors, chemokine

Mesh:

Substances:

Year:  2018        PMID: 30317773     DOI: 10.3760/cma.j.issn.1007-3418.2018.07.006

Source DB:  PubMed          Journal:  Zhonghua Gan Zang Bing Za Zhi        ISSN: 1007-3418


  4 in total

1.  CXCR3 confers sorafenib resistance of HCC cells through regulating metabolic alteration and AMPK pathway.

Authors:  Ying Ren; Yue Kai Gu; Zhen Li; Guang Zi Xu; Yang Meng Zhang; Min Xin Dong; Ying Wang; Xi Bing Zhou
Journal:  Am J Transl Res       Date:  2020-03-15       Impact factor: 4.060

2.  Downregulation of the CCL2/CCR2 and CXCL10/CXCR3 axes contributes to antitumor effects in a mouse model of malignant glioma.

Authors:  Kenji Shono; Izumi Yamaguchi; Yoshifumi Mizobuchi; Hiroshi Kagusa; Akiko Sumi; Toshitaka Fujihara; Kohei Nakajima; Keiko T Kitazato; Kazuhito Matsuzaki; Hideyuki Saya; Yasushi Takagi
Journal:  Sci Rep       Date:  2020-09-17       Impact factor: 4.379

3.  Immune Cluster and PPI Network Analyses Identified CXCR3 as a Key Node of Immunoregulation in Head and Neck Cancer.

Authors:  Ping Wang; Yanli Wang; Yuanjun Jiang; Minghong Li; Guang Li; Qiao Qiao
Journal:  Front Oncol       Date:  2021-01-15       Impact factor: 6.244

4.  CXCL9 secreted by tumor-associated dendritic cells up-regulates PD-L1 expression in bladder cancer cells by activating the CXCR3 signaling.

Authors:  Weigang Xiu; Jingjing Luo
Journal:  BMC Immunol       Date:  2021-01-06       Impact factor: 3.615

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.